

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
24 June 2021 (24.06.2021)



(10) International Publication Number
WO 2021/127528 A1

(51) International Patent Classification:

C07K 16/28 (2006.01) A61P 35/00 (2006.01)
C07K 16/30 (2006.01) A61K 39/00 (2006.01)

(21) International Application Number:

PCT/US2020/066157

(22) International Filing Date:

18 December 2020 (18.12.2020)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/951,408 20 December 2019 (20.12.2019) US

(71) Applicant: **AMGEN INC.** [US/US]; One Amgen Center Drive, Thousand Oaks, California 91320-1799 (US).

(72) Inventors: **YU, Xin**; One Amgen Center Drive, Law Dept - Patent Operations, MS 28-5-A, Thousand Oaks, California 91320-1799 (US). **EGEN, Jackson**; One Amgen Center Drive, Law Dept - Patent Operations, MS 28-5-A, Thousand Oaks, California 91320-1799 (US). **GARCES, Fernando**; One Amgen Center Drive, Law Dept - Patent Operations, MS 28-5-A, Thousand Oaks, California 91320-1799 (US). **TAKENAKA, Shunsuke**; One Amgen Center Drive, Law Dept - Patent Operations, MS 28-5-A, Thousand Oaks, California 91320-1799 (US). **KIM, AeRyon**; One Amgen Center Drive, Law Dept - Patent Operations, MS 28-5-A, Thousand Oaks, California 91320-1799 (US). **SAWANT, Deepali**; One Amgen Center Drive, Law Dept -

Patent Operations, MS 28-5-A, Thousand Oaks, California 91320-1799 (US).


(74) Agent: **DERMOTT, Jonathan M.**; One Amgen Center Drive, Law Department - Patent Operations, M/S 28-5-A, Thousand Oaks, California 91320-1799 (US).

(81) Designated States (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(54) Title: MESOTHELIN-TARGETED CD40 AGONISTIC MULTISPECIFIC ANTIBODY CONSTRUCTS FOR THE TREATMENT OF SOLID TUMORS

Figure 3. Bivalent bispecific antibody formats



(57) Abstract: The present invention relates to a human agonistic CD40 multispecific antibody construct for treatment of solid tumors by engineering a molecule that specifically targets the CD40 pathway on tumor-associated APCs, without systemic CD40 activation.

[Continued on next page]

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
- *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*
- *with sequence listing part of description (Rule 5.2(a))*